Article

WS7.3 VX-661, an investigational CFTR corrector, in combination with ivacaftor, a CFTR potentiator, in patients with CF and homozygous for the F508Del-CFTR mutation: Interim analysis

2013-06-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Cystic Fibrosis Research Advances

Identifiers and source

Literature Corpus work: b31a988a-eaa4-57e9-838e-787d76f15726
DOI: 10.1016/s1569-1993(13)60042-9

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

WS7.3 VX-661, an investigational CFTR corrector, in combination with ivacaftor, a CFTR potentiator, in patients with CF and homozygous for the F508Del-CFTR mutation: Interim analysisDOI 10.1016/s1569-1993(13)60042-9Read

Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutationSemantic proximity Read

Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two<i>F508del</i>allelesSemantic proximity Read

Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251).Semantic proximity Read

Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.Semantic proximity Read

Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies.Semantic proximity Read

Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR.Semantic proximity Read

The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis.Semantic proximity Read

Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.Semantic proximity Read

Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosisSemantic proximity Read

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.Semantic proximity Read

Combination potentiator ('co-potentiator') therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators.Semantic proximity Read

Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation.Semantic proximity Read